Last reviewed · How we verify
THR-687 dose level 3
THR-687 dose level 3 is a Small molecule drug developed by ThromboGenics. It is currently in Phase 1 development.
THR-687 is being studied in a Phase 2 clinical trial for the treatment of Diabetic Macular Edema, among other conditions. The study is evaluating multiple dose levels of THR-687, including dose level 3, as part of a randomized, multicentre trial.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | THR-687 dose level 3 |
|---|---|
| Sponsor | ThromboGenics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema. (PHASE2)
- A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- THR-687 dose level 3 CI brief — competitive landscape report
- THR-687 dose level 3 updates RSS · CI watch RSS
- ThromboGenics portfolio CI
Frequently asked questions about THR-687 dose level 3
What is THR-687 dose level 3?
Who makes THR-687 dose level 3?
What development phase is THR-687 dose level 3 in?
Related
- Manufacturer: ThromboGenics — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing